WO2005066142A2 - Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists - Google Patents

Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists Download PDF

Info

Publication number
WO2005066142A2
WO2005066142A2 PCT/JP2005/000319 JP2005000319W WO2005066142A2 WO 2005066142 A2 WO2005066142 A2 WO 2005066142A2 JP 2005000319 W JP2005000319 W JP 2005000319W WO 2005066142 A2 WO2005066142 A2 WO 2005066142A2
Authority
WO
WIPO (PCT)
Prior art keywords
alkyl
cycloalkyl
hydrogen
alkoxy
different
Prior art date
Application number
PCT/JP2005/000319
Other languages
French (fr)
Other versions
WO2005066142A3 (en
Inventor
Atsuro Nakazato
Taketoshi Okubo
Dai Nozawa
Tomoko Tamita
Ludo E.J. Kennis
Original Assignee
Taisho Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taisho Pharmaceutical Co., Ltd. filed Critical Taisho Pharmaceutical Co., Ltd.
Priority to US10/584,946 priority Critical patent/US8106194B2/en
Priority to EP05703558A priority patent/EP1706410A2/en
Priority to JP2006546614A priority patent/JP4742273B2/en
Priority to CN2005800020220A priority patent/CN1910185B/en
Priority to CA2552503A priority patent/CA2552503C/en
Publication of WO2005066142A2 publication Critical patent/WO2005066142A2/en
Publication of WO2005066142A3 publication Critical patent/WO2005066142A3/en
Priority to HK07103339.7A priority patent/HK1097539A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc.
  • CCF corticotropin releasing factor
  • CRF is a hormone comprising 41 amino acids (Science, 213, 1394-1397, 1981; and J. Neurosci., 7, 88-100, 1987), and it is suggested that CRF plays a core role in biological reactions against stresses (Cell. Mol. Neurobiol., 14, 579-588, 1994; Endocrinol, 132, 723-728, 1994; and Neuroendocrinol. 61, 445-452, 1995).
  • CRF CRF Releasing Factor: Basic and Clinical Studies of a Neuropeptide, pp. 29-52, 1990.
  • Intraventricular administration of CRF to hypophy- sectomized rats and normal rats causes an anxiety-like symptom in both types of rats (Pharmacol. Rev., 43, 425-473, 1991; and Brain Res. Rev., 15, 71-100, 1990). That is, there are suggested the participation of CRF in hypothalamus-pituitary-adrenal system and the pathway by which CRF functions as a neurotransmitter in central nervous system.
  • CRF CRF is involved (Pharmacol. Rev., 43, 425-474, 1991). That is, CRF is involved in depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, inflammation, immunity-related diseases, etc. It has recently been reported that
  • CRF CRF is involved also in epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, and cephalic external wound (Brain Res. 545, 339-342, 1991; Ann. Neurol. 31, 48-498, 1992; Dev. Brain Res. 91, 245-251, 1996; and Brain Res. 744, 166-170,
  • WO98/35967 discloses pyrrolopyrimidines or pyrrolotriazine derivatives respectively as CRF receptor antagonists. However, none disclose the compounds provided in the present invention.
  • An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc.
  • diseases in which CRF is considered to be involved such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc.
  • the present inventors earnestly investigated pyrrolopyrimidines or pyrrolotriazines substituted with a carbamoyl group that have a high affinity for CRF receptors, whereby the present invention has been accomplished.
  • the present invention is pyrrolopyrimidine or pyrrolotriazine derivatives substituted with a carbamoyl group explained below.
  • E is N or CR 10 ;
  • R 1 is -OR 4 , -S(O) ⁇ R 4 or -NR 4 R 5 ;
  • R 2 is hydrogen, C ⁇ -6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-6 alkyl, halogen, C ⁇ -6 alkoxy, C 3-7 cycloalkyloxy, C ⁇ -6 alkylthio or -N(R 6 )R 7 ;
  • R 3 is hydrogen, C ⁇ -6 alkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C ⁇ _ 6 alkyl or aryl;
  • R 4 and R 5 are the same or different, and independently hydrogen, Ci.palkyl, C 3-7 cycloalkyl, C 3-7 cycloalkyl-C 1-6 alkyl, di(C 3-7 cycloalkyl)-C 1-6 alkyl, C ⁇ -6 alkoxy-C ⁇ .
  • R 4 and R 5 are taken together to form - (CH 2 ) m -A-(CH 2 ) n - wherein A is methylene, oxygen, sulfur, NR 8 or CHR 9 ; R and R 7 are the same or different, and independently hydrogen or C ⁇ _ 6 alkyl; R 8 is hydrogen, C 1-6 alkyl, C 3-7 cycloalkyl, aryl or aryl-C 1-6 alkyl; R 9 is hydrogen, hydroxy, hydroxy-C ⁇ -6 alkyl, cyano or cyano-Ci- ⁇ alkyl; R 10 is hydrogen, halogen or C 1-6 alkyl; 1 is an interger selected from 0, 1 and 2; m
  • C 1-9 alkyl means a straight chain or branched chain alkyl group of 1 to 9 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl, sec-butyl, pentyl, isopentyl, 1-methylbutyl, hexyl, isohexyl, 1-ethylpropyl, 1- ethylbutyl, 1,3-dimethylbutyl, 1-propylbutyl, 1-propylpentyl, 1-butylpentyl or the like.
  • C 3 _ 7 cycloalkyl means a cyclic alkyl group of 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or the like.
  • Cs ⁇ cycloalkyl-C ⁇ ealkyl means a substituted C 1-6 alkyl group having the above-mentioned C 3-7 cycloalkyl as the substituent, such as cyclopropylmethyl, 1-cyclopropylethyl, 1-cyclobutylethyl, 1-cyclopentylethyl, 2- cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, 1-cyclopropylpropyl, 1- cyclobutylpropyl, 1-cyclopentylpropyl, 1-cyclopropylmethylpropyl, 1- cyclopropylmethylbutyl or the like.
  • C 3-8 cycloalkyloxy means a cyclic alkoxy group of 3 to 8 carbon atoms, such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or the like.
  • di(C 3-7 cycloalkyl)-C 1-6 alkyl means a substituted C ⁇ -6 alkyl group having two above-mentioned C 3- cycloalkyl groups as the substituents, such as di(cyclopropyl)methyl, di(cyclobutyl)methyl, di(cyclopentyl)methyl or the like.
  • C ⁇ -6 alkoxy means a straight chain or branched chain alkoxy group of 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropyloxy, butoxy, isobutyloxy, pentyloxy, isopentyloxy or the like.
  • C 1-6 alkoxy-C ⁇ -6 alkyl means a substituted C 1-6 alkyl group having the above-mentioned C 1-6 alkoxy group as the substituent, such as methoxymethyl, 2- methoxyethyl, 2-ethoxyethyl, 1-methoxymethylpropyl, 1-methoxymethylbutyl or the like.
  • di(C ⁇ -6 alkoxy)-C 1-6 alkyl means a substituted C 1-6 alkyl group having two above-mentioned C 1-6 alkoxy groups as the substituents, such as 2,3- di(methoxy)propyl, 2-methoxy-l-methoxymethyl-ethyl, 2,4-di(ethoxy)pentyl or the like.
  • hydroxy-C 1-6 alkyl means a substituted d- 6 alkyl group having a hydroxy group, such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1- hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 5- hydroxypentyl, l-hydroxymethylpropyl, 1-hydroxymethylbutyl, l-hydroxymethyl-3- methylbutyl or the like.
  • cyano-C ⁇ -6 alkyr means a substituted C 1-6 alkyl group having a cyano group, such as cyanomethyl, 1-cyanoethyl, 2-cyanoethyl, 1-cyanopropyl, 1- cyanobutyl, 5-cyanopentyl, 2-cyano-l-ethylethyl, 1-cyanomethylbutyl, l-cyano-3- methylbutyl, l-cyanomethyl-3 -methyl-butyl or the like.
  • carbamoyl-C 1-6 alkyl means a substituted C 1-6 alkyl group having a carbamoyl group, such as carbamoylmethyl, 1-carbamoylethyl, 2-carbamoylethyl, 1-carbamoylpropyl, 1-carbamoylbutyl, 5-carbamoylpentyl, l-carbamoyl-3- methylbutyl, 1-carbamoylmethylbuty, 1-carbamoylmethylpropyl, 1- carbamoylmethyl-3-methylbutyl or the like.
  • di(C ⁇ -6 alkyl)amino means a amino group having two above- mentioned C 1-6 alkyl groups, such as dimethylamino, diethylamino, dipropylamino or the like.
  • di(C ⁇ -6 alkyl)amino-C 2-6 alkyl means a substituted C 2-6 alkyl group having a above-mentioned di(C 1-6 alkyl)amino group, such as 2- dimethylaminoethyl, 3-dimethylaminopropyl or the like.
  • aryl means a monocyclic or bicyclic group of 6 to 12 ring carbon atoms having at least one aromatic ring, such as phenyl, naphthyl, or the like.
  • heteroaryl means a monocyclic or bicyclic group of 5 to 12 ring atoms having at least one aromatic ring having in its ring 1 to 4 atoms which may be the same or different and are selected from nitrogen, oxygen and sulfur, such as pyridyl, pyrimidinyl, imidazolyl, quinolyl, indolyl, benzofuranyl, quinoxalinyl, benzo[l,2,5]thiadiazolyl, benzo[l,2,5]oxadiazolyl or the like.
  • ary-C salkyl means a substituted Ci-salkyl group having the above-mentioned aryl as the substituent, such as benzyl, phenethyl or the like.
  • halogen means fluorine, chlorine, bromine or iodine atom.
  • C 2-6 alkenyl means a straight chain or branched chain alkenyl group of 2 to 6 carbon atoms, such as vinyl, isopropenyl, allyl or the like.
  • C 2-6 alkynyl means a straight chain or branched chain alkynyl group of 2 to 6 carbon atoms, such as ethynyl, prop-1-ynyl, prop-2-ynyl or the like.
  • C ⁇ -6 alkylthio means a straight chain or branched chain alkylthio group of 1 to 6 carbon atoms, such as methylthio, ethylthio, propylthio or the like.
  • aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C 1-6 alkyl, C 3-7 cycloalkyl, C 2-6 alkenyl, C 2-
  • the "pharmaceutically acceptable salts" in the present invention include, for example, salts with an inorganic acid such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid or the like; salts with an organic acid such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid, jp-toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid or the like; salts with one or more metal ions such as lithium ion, sodium ion, potassium ion, calcium ion, magnesium ion, zinc
  • isomers such as diastereomers, enantiomers, geometricisomers and tautomeric forms may exist.
  • the compound of the present invention includes the individual isomers and the racemic and non- racemic mixtures of the isomers.
  • R 1 , R 2 , R 3 and Ar are as defined in formula [I]. More preferable are compounds of the formula [II], wherein R 1 is -OR 4 or -NR 4 R 5 ; R 2 is C 1-6 alkyl; R 3 is hydrogen or C 1-6 alkyl; R 4 and R 5 are the same or different, and independently hydrogen, C 1-9 alkyl, C 3- 7 cycloalkyl, C 3- cycloalkyl-C ⁇ . 6 alkyl, di(C 3-7 cycloalkyl)-C ⁇ -6 alkyl, C 1-6 alkoxy-C ⁇ .
  • Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C 1-3 alkyl, C ⁇ -3 alkoxy, C ⁇ _ 3 alkylthio, trifluoromethyl, trifluoromethoxy and -N(R 20 )R 21 (wherein R 20 and R 21 are the same or different, and independently are hydrogen or C ⁇ -3 alkyl); More preferable are compounds of the formula [II], wherein R 1 is -OR 4 or -NR 4 R 5 ; R 2 is C ⁇ -6 alkyl; R 3 is hydrogen or C ⁇ -6 alkyl; R 4 is C ⁇ alkyl, C 3 - 7 cycloalkyl, C 3 - 7 cycloalkyl- C ⁇ -6 alkyl;
  • R 1 , R 2 , R 3 and Ar are as defined in formula [I]. More preferable are compounds of the formula [III], wherein R 1 is -OR 4 or -NR 4 R 5 ; R 2 is C ⁇ -6 alkyl; R 3 is hydrogen or C 1-6 alkyl; R 4 and R 5 are the same or different, and independently hydrogen, -palkyl, C 3-7 cycloalkyl, C 3- 7 cycloalkyl-C 1 _ 6 alkyl, di(C 3 _ 7 cycloalkyl)-C 1-6 alkyl, C 1-6 alkoxy-C ⁇ -6 alkyl, di(C 1- 6 alkoxy)-C ⁇ -6 alkyl, hydroxy-C ⁇ -6 alkyl or cyano-C 1-6 alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C ⁇
  • R 5 is hydrogen
  • Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C 1-3 alkyl.
  • the compound of the formula [I] can be produced, for example, by the process shown in the following reaction scheme 1 (in the following reaction scheme, R 1 , R 2 , R 3 and Ar are as defined above, LG is chloro, bromo, iodo, methanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy or trifluoromethanesulfonyloxy group, R a is C 1-6 alkyl or benzyl, p is 1 or 2).
  • Step l Compound (2) can be obtained by reacting Compound (1) with the corresponding amine in an inert solvent in the presence or absence of a base.
  • the base includes, for example, amines such as triethylamine, N,N- diisopropylethylamine, pyridine and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, barium hydroxide, sodium hydride and the like; metal alcoholates such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like; metal amides such as sodium amide, lithium dusopropylamide and the like; and Grignard reagents such as methylmagnesium bromide and the like.
  • the inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; hydrocarbons such as benzene, toluene, xylene and the like; esters such as ethyl acetate, ethyl formate; amides such as N,N- dimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.
  • alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like
  • ethers such as diethyl ether, tetrahydr
  • Step 2 Conversion of a cyano group in Compound (2) into a carbamoyl group can be achieved in the presence of an acid or a base in the presence or absence of an inert solvent.
  • R 1 has a cyano group
  • the cyano group can be converted into a carbamoyl group at the same time.
  • the acid includes inorganic acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, polyphosphoric acid nitric acid and the like; organic acids such as benzenesulfonic acid, toluenesulfonic acid and the like.
  • the base includes inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide, aluminium hydroxide and the like.
  • the inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, tert- butyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene and the like; amides such as N,N-dimethylformamide, N- methylpyrrolidone, N,N-dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.
  • the compound of the present invention can be converted to a salt with an acid in an inert solvent.
  • the acid includes inorganic acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid and the like; organic acids such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid,p- toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid and the like.
  • the inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene and the like; amides such as N,N-dimethylformamide, N- methylpyrrolidone, N,N-dimethylacetamide and the like; esters such as ethyl acetate, ethyl formate and the like; ketones such as acetone, methylethylketone and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.
  • alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the
  • Step 3 Conversion of Compound (4) into Compound (5) can be carried out by treatment of (4) with thiourea in an inert solvent and followed by reacting with an alkylating reagent in the presence or absence of a base in an inert solvent.
  • the alkylating reagent includes conventional alkylating reagents such as methyl iodide, methyl bromide, dimethyl sulfate, ethyl iodide, ethyl bromide, diethyl sulfate, benzyl chloride, benzyl bromide and the like.
  • the base includes amines such as triethylamine, NN-diisopropylethylamine, pyridine and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, barium hydroxide, sodium hydride and the like; metal alcoholates such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like; metal amides such as sodium amide, lithium dusopropylamide and the like; and Grignard reagents such as methylmagnesium bromide and the like.
  • amines such as triethylamine, NN-diisopropylethylamine, pyridine and the like
  • inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, barium hydroxide, sodium hydride and the like
  • the inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; hydrocarbons such as benzene, toluene, xylene and the like; amides such as N,N-dimethylformamide, N-methylpyrrolidone, N,N- dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.
  • alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like
  • ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxye
  • Step 4 Conversion of Compound (5) into Compound (6) can be achieved in the same manner as step 2.
  • Step 5 Conversion of Compound (6) into Compound (7) can be carried out by reacting Compound (6) with an oxidizing reagent in an inert solvent.
  • the oxidizing reagent includes conventional oxidizing reagents to oxidize a sulfide group such as peroxyacetic acid, hydrogen peroxide, 3-chloroperoxybenzoic acid, Oxone, sodium periodate, sodium perborate and the like.
  • the inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; hydrocarbons such as benzene, toluene, xylene and the like; amides such as N,N-dimethylformamide, N-methylpyrrolidone, N,N- dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.
  • alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like
  • ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxye
  • Step 6 Conversion of Compound (7) into Compound (8) can be carried out in the same manner as step 1.
  • the compound of the present invention is useful as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved.
  • the compound of the present invention can be formulated into tablets, pills, capsules, granules, powders, solutions, emulsions, suspensions, injections and the like by a conventional preparation technique by adding conventional fillers, binders, disintegrators, pH-adjusting agents, solvents, etc.
  • the compound of the present invention can be administered to an adult patient in a dose of 0.1 to 500 mg per day in one portion or several portions orally or parenterally. The dose can be properly increased or decreased depending on the kind of a disease and the age, body weight and symptom of a patient.
  • Table 1 and table 2 list the compound obtained in Example 1 and compounds obtained by the similar procedure as described in Example 1.
  • Table 1 lists the compound obtained in Example 2 and compounds obtained by the similar procedure as described in Example 2.
  • EDTA 0.1% bovine serum albumin and 100 kallikrein units/ml aprotinin, to obtain a membrane preparation.
  • CRF receptor binding test The membrane preparation (0.3 mg protein/ml), 125 I-CRF (0.2 nM) and a test drug were reacted at 25°C for 2 hours. After completion of the reaction, the reaction mixture was filtered by suction through a glass filter (GF/C) treated with
  • 1-006, 1-007, 1-008, 1-009, 1-010, 1-011, 1-012, 1-013, 1-016, 1-017, 1-018, 1-019, 1-022, 1-027, 2-001, 2-002, 2-003, 2-004, 2-005 and 2-006 can be exemplified as typical compounds having an IC 5 0 value of 100 nM or less.
  • CRF CRF receptors
  • These compounds are effective against diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc.
  • diseases in which CRF is considered to be involved such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Addiction (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]: has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.

Description

DESCRIPTION PYRROLOPYRIMIDINE AND PYRROLOTRIAZINE DERIVATIVES
DETAILED DESCRIPTION OF THE INVENTION TECHNICAL FIELD The present invention relates to a therapeutic agent for diseases in which corticotropin releasing factor (CRF) is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, pain, etc.
DESCRIPTION OF THE PRIOR ART CRF is a hormone comprising 41 amino acids (Science, 213, 1394-1397, 1981; and J. Neurosci., 7, 88-100, 1987), and it is suggested that CRF plays a core role in biological reactions against stresses (Cell. Mol. Neurobiol., 14, 579-588, 1994; Endocrinol, 132, 723-728, 1994; and Neuroendocrinol. 61, 445-452, 1995). For CRF, there are the following two paths: a path by which CRF acts on peripheral immune system or sympathetic nervous system through hypothalamus-pituitary- adrenal system, and a path by which CRF functions as a neurotransmitter in central nervous system (in Corticotropin Releasing Factor: Basic and Clinical Studies of a Neuropeptide, pp. 29-52, 1990). Intraventricular administration of CRF to hypophy- sectomized rats and normal rats causes an anxiety-like symptom in both types of rats (Pharmacol. Rev., 43, 425-473, 1991; and Brain Res. Rev., 15, 71-100, 1990). That is, there are suggested the participation of CRF in hypothalamus-pituitary-adrenal system and the pathway by which CRF functions as a neurotransmitter in central nervous system. The review by Owens and Nemeroff in 1991 summarizes diseases in which
CRF is involved (Pharmacol. Rev., 43, 425-474, 1991). That is, CRF is involved in depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastrointestinal diseases, drug dependence, inflammation, immunity-related diseases, etc. It has recently been reported that
CRF is involved also in epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, and cephalic external wound (Brain Res. 545, 339-342, 1991; Ann. Neurol. 31, 48-498, 1992; Dev. Brain Res. 91, 245-251, 1996; and Brain Res. 744, 166-170,
1997). Accordingly, antagonists against CRF receptors are useful as therapeutic agents for the diseases described above. WO98/35967 discloses pyrrolopyrimidines or pyrrolotriazine derivatives respectively as CRF receptor antagonists. However, none disclose the compounds provided in the present invention.
PROBLEM(S) TO BE SOLVED BY INVENTION An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc.
MEANS FOR SOLVING PROBLEM The present inventors earnestly investigated pyrrolopyrimidines or pyrrolotriazines substituted with a carbamoyl group that have a high affinity for CRF receptors, whereby the present invention has been accomplished. The present invention is pyrrolopyrimidine or pyrrolotriazine derivatives substituted with a carbamoyl group explained below. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]:
Figure imgf000003_0001
(wherein E is N or CR10; R1 is -OR4, -S(O)ιR4 or -NR4R5; R2 is hydrogen, Cι-6alkyl, C3-7cycloalkyl, C3-7cycloalkyl-C1-6alkyl, halogen, Cι-6alkoxy, C3-7cycloalkyloxy, Cι-6alkylthio or -N(R6)R7; R3 is hydrogen, Cι-6alkyl, C3-7cycloalkyl, C3-7cycloalkyl-Cι_6alkyl or aryl; R4 and R5 are the same or different, and independently hydrogen, Ci.palkyl, C3-7cycloalkyl, C3-7cycloalkyl-C1-6alkyl, di(C3-7cycloalkyl)-C1-6alkyl, Cι-6alkoxy-Cι. 6alkyl, di(C1-6alkoxy)-Cι-6alkyl, hydroxy-C1-6alkyl, cyano-C1-6alkyl, carbamoyl- . 6alkyl or di(C1-6alkyl)amino-C2-6alkyl; or R4 and R5 are taken together to form - (CH2)m-A-(CH2)n- wherein A is methylene, oxygen, sulfur, NR8 or CHR9; R and R7 are the same or different, and independently hydrogen or Cι_ 6alkyl; R8 is hydrogen, C1-6alkyl, C3-7cycloalkyl, aryl or aryl-C1-6alkyl; R9 is hydrogen, hydroxy, hydroxy-Cι-6alkyl, cyano or cyano-Ci-βalkyl; R10 is hydrogen, halogen or C1-6alkyl; 1 is an interger selected from 0, 1 and 2; m is an integer selected from 1, 2, 3 and 4; n is an integer selected from 0, 1, 2 and 3; with the proviso, when A is oxygen, sulfur or NR8, then n is 1, 2 or 3; Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, Cι-6alkyl, C3-7cycloalkyl, C2-6alkenyl, C2_ 6alkynyl, Cι-6alkoxy, C1-6alkylthio, Cι-6alkylsulfϊnyl, C1-6alkylsulfonyl, cyano, nitro, hydroxy, -CO2Rπ, -C(=O)R12, -CONR13R14, -OC(=O)R15, -NR16CO2R17, - S(=O)rNR18R19, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R20)R21; R11 and R17 are the same or different, and independently are hydrogen, Ci- 5alkyl, C3-8cycloalkyl, C3-8cycloalkyl-Cι-5alkyl, aryl or aryl-C1-5alkyl; R12, R13, R14, R15, R16, R18, R19, R20 and R21 are the same or different, and independently are hydrogen, Ci-salkyl or C3-8cycloalkyl; r is 1 or 2), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof. The terms used in the present specification have the following meanings. The term "C1-9alkyl" means a straight chain or branched chain alkyl group of 1 to 9 carbon atoms, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert- butyl, sec-butyl, pentyl, isopentyl, 1-methylbutyl, hexyl, isohexyl, 1-ethylpropyl, 1- ethylbutyl, 1,3-dimethylbutyl, 1-propylbutyl, 1-propylpentyl, 1-butylpentyl or the like. The term "C3_7cycloalkyl" means a cyclic alkyl group of 3 to 7 carbon atoms, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl or the like. The term "Cs^cycloalkyl-C^ealkyl" means a substituted C1-6alkyl group having the above-mentioned C3-7cycloalkyl as the substituent, such as cyclopropylmethyl, 1-cyclopropylethyl, 1-cyclobutylethyl, 1-cyclopentylethyl, 2- cyclopropylethyl, 2-cyclobutylethyl, 2-cyclopentylethyl, 1-cyclopropylpropyl, 1- cyclobutylpropyl, 1-cyclopentylpropyl, 1-cyclopropylmethylpropyl, 1- cyclopropylmethylbutyl or the like. The term "C3-8cycloalkyloxy" means a cyclic alkoxy group of 3 to 8 carbon atoms, such as cyclopropyloxy, cyclobutyloxy, cyclopentyloxy or the like. The term "di(C3-7cycloalkyl)-C1-6alkyl" means a substituted Cι-6alkyl group having two above-mentioned C3- cycloalkyl groups as the substituents, such as di(cyclopropyl)methyl, di(cyclobutyl)methyl, di(cyclopentyl)methyl or the like. The term "Cι-6alkoxy" means a straight chain or branched chain alkoxy group of 1 to 6 carbon atoms, such as methoxy, ethoxy, propoxy, isopropyloxy, butoxy, isobutyloxy, pentyloxy, isopentyloxy or the like. The term "C1-6alkoxy-Cι-6alkyl" means a substituted C1-6alkyl group having the above-mentioned C1-6alkoxy group as the substituent, such as methoxymethyl, 2- methoxyethyl, 2-ethoxyethyl, 1-methoxymethylpropyl, 1-methoxymethylbutyl or the like. The term "di(Cι-6alkoxy)-C1-6alkyl" means a substituted C1-6alkyl group having two above-mentioned C1-6alkoxy groups as the substituents, such as 2,3- di(methoxy)propyl, 2-methoxy-l-methoxymethyl-ethyl, 2,4-di(ethoxy)pentyl or the like. The term "hydroxy-C1-6alkyl" means a substituted d-6alkyl group having a hydroxy group, such as hydroxymethyl, 1-hydroxyethyl, 2-hydroxyethyl, 1- hydroxypropyl, 2-hydroxypropyl, 3-hydroxypropyl, 4-hydroxybutyl, 5- hydroxypentyl, l-hydroxymethylpropyl, 1-hydroxymethylbutyl, l-hydroxymethyl-3- methylbutyl or the like. The term "cyano-Cι-6alkyr means a substituted C1-6alkyl group having a cyano group, such as cyanomethyl, 1-cyanoethyl, 2-cyanoethyl, 1-cyanopropyl, 1- cyanobutyl, 5-cyanopentyl, 2-cyano-l-ethylethyl, 1-cyanomethylbutyl, l-cyano-3- methylbutyl, l-cyanomethyl-3 -methyl-butyl or the like. The term "carbamoyl-C1-6alkyl" means a substituted C1-6alkyl group having a carbamoyl group, such as carbamoylmethyl, 1-carbamoylethyl, 2-carbamoylethyl, 1-carbamoylpropyl, 1-carbamoylbutyl, 5-carbamoylpentyl, l-carbamoyl-3- methylbutyl, 1-carbamoylmethylbuty, 1-carbamoylmethylpropyl, 1- carbamoylmethyl-3-methylbutyl or the like. The term "di(Cι-6alkyl)amino" means a amino group having two above- mentioned C1-6alkyl groups, such as dimethylamino, diethylamino, dipropylamino or the like. The term "di(Cι-6alkyl)amino-C2-6alkyl" means a substituted C2-6alkyl group having a above-mentioned di(C1-6alkyl)amino group, such as 2- dimethylaminoethyl, 3-dimethylaminopropyl or the like. The term "aryl" means a monocyclic or bicyclic group of 6 to 12 ring carbon atoms having at least one aromatic ring, such as phenyl, naphthyl, or the like. The term "heteroaryl" means a monocyclic or bicyclic group of 5 to 12 ring atoms having at least one aromatic ring having in its ring 1 to 4 atoms which may be the same or different and are selected from nitrogen, oxygen and sulfur, such as pyridyl, pyrimidinyl, imidazolyl, quinolyl, indolyl, benzofuranyl, quinoxalinyl, benzo[l,2,5]thiadiazolyl, benzo[l,2,5]oxadiazolyl or the like. The term "ary-C salkyl" means a substituted Ci-salkyl group having the above-mentioned aryl as the substituent, such as benzyl, phenethyl or the like. The term "halogen" means fluorine, chlorine, bromine or iodine atom. The term "C2-6alkenyl" means a straight chain or branched chain alkenyl group of 2 to 6 carbon atoms, such as vinyl, isopropenyl, allyl or the like. The term "C2-6alkynyl" means a straight chain or branched chain alkynyl group of 2 to 6 carbon atoms, such as ethynyl, prop-1-ynyl, prop-2-ynyl or the like. The term "Cι-6alkylthio" means a straight chain or branched chain alkylthio group of 1 to 6 carbon atoms, such as methylthio, ethylthio, propylthio or the like. The phrase "aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, C2-
6alkynyl, C1-6alkoxy, Cι-6alkylthio, C1-6alkylsulfmyl, C1-6alkylsulfonyl, cyano, nitro, hydroxy, -CO2R9, -C(=O)R10, -CONRπR12, -OC(=O)R13, -NR14CO2R15, -
S(=O)rNR16R17, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R18)R19" includes, for example, 2,4-dimethylphenyl, 2,6-dimethylphenyl,
2,4-dibromophenyl, 2-bromo-4-isoproylphenyl, 2,4-dichlorophenyl, 2,6- dichlorophenyl, 2-chloro-4-trifluoromethylphenyl, 4-methoxy-2-methylphenyl, 2- chloro-4-trifluoromethoxyphenyl, 4-isopropyl-2-methylthiophenyl, 2,4,6- trimethylphenyl, 4-bromo-2,6-dimethylphenyl, 4-bromo-2,6-diethylphenyl, 4- chloro-2,6-dimethylphenyl, 2,4,6-tribromophenyl, 2,4,5-tribromophenyl, 2,4,6- trichlorophenyl, 2,4,5-trichlorophenyl, 4-bromo-2,6-dichlorophenyl, 6-chloro-2,4- dibromophenyl, 2,4-dibromo-6-fluorophenyl, 2,4-dibromo-6-methylphenyl, 2,4- dibromo-6-methoxyphenyl, 2,4-dibromo-6-methylthiophenyl, 2,6-dibromo-4- isopropylphenyl, 2,6-dibromo-4-trifluoromethylphenyl, 2-bromo-4- trifluoromethylphenyl, 4-bromo-2-chlorophenyl, 2-bromo-4-chlorophenyl, 4-bromo- 2-methylphenyl, 4-chloro-2-methylphenyl, 2,4-dimethoxyphenyl, 2,6-dimethyl-4- methoxyphenyl, 4-chloro-2,6-dibromophenyl, 4-bromo-2,6-difluorophenyl, 2,6- dichloro-4-trifluoromethylphenyl, 2,6-dichloro-4-trifluoromethoxyphenyl, 2,6- dibromo-4-trifluoromethoxyphenyl, 2-chloro-4,6-dimethylphenyl, 2-bromo-4,6- dimethoxyphenyl, 2-bromo-4-isopropyl-6-methoxyphenyl, 2,4-dimethoxy-6- methylphenyl, 6-dimethylamino-4-methylpyridin-3-yl, 2-chloro-6-trifluoromethyl- pyridin-3 -yl, 2-chloro-6-trifluoromethoxypyridin-3 -yl, 2-chloro-6-methoxypyridin- 3-yl, 6-methoxy-2-trifluoromethylpyridin-3-yl, 2-chloro-6-difluoromethylpyridin-3- yl, 6-methoxy-2-methylpyridin-3-yl, 2,6-dimethoxypyridin-3-yl, 4,6-dimethyl-2- trifluoromethylpyrimidin-5-yl and 2-dimethylamino-6-methylpyridin-3-yl. The "pharmaceutically acceptable salts" in the present invention include, for example, salts with an inorganic acid such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid or the like; salts with an organic acid such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid, jp-toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid or the like; salts with one or more metal ions such as lithium ion, sodium ion, potassium ion, calcium ion, magnesium ion, zinc ion, aluminium ion or the like; salts with an amine such as ammonia, arginine, lysine, piperazine, choline, diethylamine, 4-phenylcyclohexylamine, 2-aminoethanol, benzathine or the like. In a compound of the present invention, isomers such as diastereomers, enantiomers, geometricisomers and tautomeric forms may exist. The compound of the present invention includes the individual isomers and the racemic and non- racemic mixtures of the isomers.
Preferable examples of the compound of the present invention are as follows.
Figure imgf000008_0001
That is preferable are compounds of the formula [II] in which R1, R2, R3 and Ar are as defined in formula [I]. More preferable are compounds of the formula [II], wherein R1 is -OR4 or -NR4R5; R2 is C1-6alkyl; R3 is hydrogen or C1-6alkyl; R4 and R5 are the same or different, and independently hydrogen, C1-9alkyl, C3- 7cycloalkyl, C3- cycloalkyl-Cι.6alkyl, di(C3-7cycloalkyl)-Cι-6alkyl, C1-6alkoxy-Cι. 6alkyl, di(Cι-6alkoxy)-C1-6alkyl, hydroxy-Cι-6alkyl or cyano-Cι-6alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, Cι-3alkoxy, Cι_ 3alkylthio, trifluoromethyl, trifluoromethoxy and -N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or Cι-3alkyl); More preferable are compounds of the formula [II], wherein R1 is -OR4 or -NR4R5; R2 is Cι-6alkyl; R3 is hydrogen or Cι-6alkyl; R4 is C^alkyl, C3-7cycloalkyl, C3-7cycloalkyl- Cι-6alkyl, di(C3-7cycloalkyl)-C1-6alkyl, C1-6alkoxy-C1-6alkyl, di(Cι-6alkoxy)-Cι-6alkyl, hydroxy-Cι_6alkyl or cyano-C1-6alkyl; R5 is hydrogen; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and Cι-3alkyl.
Figure imgf000009_0001
Other preferable are compounds of the formula [III] in which R1, R2, R3 and Ar are as defined in formula [I]. More preferable are compounds of the formula [III], wherein R1 is -OR4 or -NR4R5; R2 is Cι-6alkyl; R3 is hydrogen or C1-6alkyl; R4 and R5 are the same or different, and independently hydrogen, -palkyl, C3-7cycloalkyl, C3- 7cycloalkyl-C1_6alkyl, di(C3_7cycloalkyl)-C1-6alkyl, C1-6alkoxy-Cι-6alkyl, di(C1- 6alkoxy)-Cι-6alkyl, hydroxy-Cι-6alkyl or cyano-C1-6alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, Cι-3alkyl, C1- alkoxy, Cι-3alkylthio, trifluoromethyl, trifluoromethoxy and -N(R )R (wherein R and R are the same or different, and independently are hydrogen or Chalky!); More preferable are compounds of the formula [III], wherein R1 is -OR4 or -NR4R5; R2 is C1-6alkyl; R3 is hydrogen or Cι-6alkyl; R4 is C1- alkyl, C3-7cycloalkyl, C3-7cycloalkyl-Cι-6alkyl, di(C3- 7cycloalkyl)-C1-6alkyl, Ci.6alkoxy-Cι-6alkyl, di(Cι-6alkoxy)-C1-6alkyl, hydroxy-Ci. 6alkyl or cyano-C1-6alkyl; R5 is hydrogen; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C1-3alkyl. The compound of the formula [I] can be produced, for example, by the process shown in the following reaction scheme 1 (in the following reaction scheme, R1, R2, R3 and Ar are as defined above, LG is chloro, bromo, iodo, methanesulfonyloxy, benzenesulfonyloxy, toluenesulfonyloxy or trifluoromethanesulfonyloxy group, Ra is C1-6alkyl or benzyl, p is 1 or 2).
Reaction Scheme 1
Figure imgf000009_0002
(1) (2) (3) Step l: Compound (2) can be obtained by reacting Compound (1) with the corresponding amine in an inert solvent in the presence or absence of a base. Herein, the base includes, for example, amines such as triethylamine, N,N- diisopropylethylamine, pyridine and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, barium hydroxide, sodium hydride and the like; metal alcoholates such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like; metal amides such as sodium amide, lithium dusopropylamide and the like; and Grignard reagents such as methylmagnesium bromide and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; hydrocarbons such as benzene, toluene, xylene and the like; esters such as ethyl acetate, ethyl formate; amides such as N,N- dimethylformamide, N-methylpyrrolidone, N,N-dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.
Step 2: Conversion of a cyano group in Compound (2) into a carbamoyl group can be achieved in the presence of an acid or a base in the presence or absence of an inert solvent. When R1 has a cyano group, the cyano group can be converted into a carbamoyl group at the same time. Herein, the acid includes inorganic acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, polyphosphoric acid nitric acid and the like; organic acids such as benzenesulfonic acid, toluenesulfonic acid and the like. The base includes inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, calcium hydroxide, magnesium hydroxide, zinc hydroxide, aluminium hydroxide and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, tert- butyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene and the like; amides such as N,N-dimethylformamide, N- methylpyrrolidone, N,N-dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents. The compound of the present invention can be converted to a salt with an acid in an inert solvent. The acid includes inorganic acids such as sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid and the like; organic acids such as acetic acid, oxalic acid, lactic acid, tartaric acid, fumaric acid, maleic acid, citric acid, benzenesulfonic acid, methanesulfonic acid,p- toluenesulfonic acid, benzoic acid, camphorsulfonic acid, ethanesulfonic acid, glucoheptonic acid, gluconic acid, glutamic acid, glycolic acid, malic acid, malonic acid, mandelic acid, galactaric acid, naphthalene-2-sulfonic acid and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2-dimethoxyethane and the like; hydrocarbons such as benzene, toluene and the like; amides such as N,N-dimethylformamide, N- methylpyrrolidone, N,N-dimethylacetamide and the like; esters such as ethyl acetate, ethyl formate and the like; ketones such as acetone, methylethylketone and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.
Reaction Scheme 2
Figure imgf000011_0001
(7) (8) Step 3: Conversion of Compound (4) into Compound (5) can be carried out by treatment of (4) with thiourea in an inert solvent and followed by reacting with an alkylating reagent in the presence or absence of a base in an inert solvent. Herein, the alkylating reagent includes conventional alkylating reagents such as methyl iodide, methyl bromide, dimethyl sulfate, ethyl iodide, ethyl bromide, diethyl sulfate, benzyl chloride, benzyl bromide and the like. The base includes amines such as triethylamine, NN-diisopropylethylamine, pyridine and the like; inorganic bases such as sodium carbonate, potassium carbonate, sodium hydrogencarbonate, potassium hydrogencarbonate, potassium hydroxide, sodium hydroxide, lithium hydroxide, barium hydroxide, sodium hydride and the like; metal alcoholates such as sodium methoxide, sodium ethoxide, potassium tert-butoxide and the like; metal amides such as sodium amide, lithium dusopropylamide and the like; and Grignard reagents such as methylmagnesium bromide and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; hydrocarbons such as benzene, toluene, xylene and the like; amides such as N,N-dimethylformamide, N-methylpyrrolidone, N,N- dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.
Step 4: Conversion of Compound (5) into Compound (6) can be achieved in the same manner as step 2.
Step 5: Conversion of Compound (6) into Compound (7) can be carried out by reacting Compound (6) with an oxidizing reagent in an inert solvent. Herein, the oxidizing reagent includes conventional oxidizing reagents to oxidize a sulfide group such as peroxyacetic acid, hydrogen peroxide, 3-chloroperoxybenzoic acid, Oxone, sodium periodate, sodium perborate and the like. The inert solvent includes, for example, alcohols such as methanol, ethanol, isopropyl alcohol, ethylene glycol and the like; ethers such as diethyl ether, tetrahydrofuran, 1,4-dioxane, 1,2- dimethoxyethane and the like; hydrocarbons such as benzene, toluene, xylene and the like; amides such as N,N-dimethylformamide, N-methylpyrrolidone, N,N- dimethylacetamide and the like; acetonitrile; dichloromethane; chloroform; dimethyl sulfoxide; pyridine; water; and mixtures of solvents selected from these inert solvents.
Step 6: Conversion of Compound (7) into Compound (8) can be carried out in the same manner as step 1. The compound of the present invention is useful as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved. For this purpose, the compound of the present invention can be formulated into tablets, pills, capsules, granules, powders, solutions, emulsions, suspensions, injections and the like by a conventional preparation technique by adding conventional fillers, binders, disintegrators, pH-adjusting agents, solvents, etc. The compound of the present invention can be administered to an adult patient in a dose of 0.1 to 500 mg per day in one portion or several portions orally or parenterally. The dose can be properly increased or decreased depending on the kind of a disease and the age, body weight and symptom of a patient.
EMBODIMENTS OF THE INVENTION The present invention is concretely explained with reference to the following examples and test example, but is not limited thereto. Example 1 Synthesis of 8-(4-bromo-2,6-dimethyl-phenyl)-2-methyl-4-(l -propyl- butylamino)-pyrrolo [ 1 ,2-α]pyrimidine-6-carboxylic acid amide hydrochloride (compound 1-001)
Figure imgf000014_0001
(1) A mixture of 8-(4-bromo-2,6-dimethyl-phenyl)-4-chloro-2-methyl- pyrrolo[l,2-α]pyrimidine-6-carbonitrile (30.0 g), 1-propyl-butylamine (18.5 g), N,N- diisopropylethylamine (15.5 g) in ethanol (90 mL) was heated at reflux for 2 h. The reaction mixture was cooled to room temperature, poured into a saturated aqueous sodium hydrogencarbonate, and then extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give a solid. The solid was washed with diisopropylether to give 8-(4-bromo-2,6-dimethyl-phenyl)-2-methyl-4- (l-propyl-butylamino)-pyrrolo[l,2-α]pyrimidine-6-carbonitrile (27.0 g).
Figure imgf000014_0002
(2) 8-(4-Bromo-2,6-dimethyl-phenyl)-2-methyl-4-(l -propyl-butylamino)- pyrrolo[l,2-_?]pyrimidine-6-carbonitrile (10.0 g) was added into cone. H2SO4 (50 mL) and heated for 55 °C for 5 hours. The reaction mixture was cooled to room temperature, poured into ice- water and then a saturated aqueous sodium hydrogencarbonate was added to make the aqueous mixture alkaline (pH = 8) and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by a silica gel column chromatography (silica gel: Wako Gel (C200), eluent: hexane / ethyl acetate / chloroform = 10 : 3 : 1) to give a solid. The solid was recrystallized from ethyl acetate to provide 8-(4-bromo-
2,6-dimethyl-phenyl)-2-methyl-4-(l-propyl-butylamino)-ρyrrolo[l,2-α]pyrimidine- 6-carboxylic acid amide (5.8 g). (3) To a suspension of 8-(4-bromo-2,6-dimethyl-phenyl)-2-methyl-4-(l- propyl-butylamino)-pyrrolo[l,2-α]pyrimidine-6-carboxylic acid amide (5.8 g) in ethanol (30 mL) was added 4 M HCl / ethyl acetate (3.7 mL) in an ice-cooling bath.
The resulting solution was concentrated under reduced pressure. The residue was crystallized from ethyl acetate to give the title compound.
Table 1 and table 2 list the compound obtained in Example 1 and compounds obtained by the similar procedure as described in Example 1.
Example 2 Synthesis of 8-(4~bromo-2,6-dimethyl-phenyl)-2-methyl-4-(N,N- dipropylamino)-pyrrolo[l,2-«]pyrimidine-6-carboxylic acid amide (compound 1- 022)
Figure imgf000015_0001
(1) A mixture of 8-(4-bromo-2,6-dimethyl-phenyl)-4-chloro-2-methyl- pyrrolo[l,2-α]pyrimidine-6-carbonitrile (7.50 g), thiourea (7.11 g) in ethanol (50 mL) was heated at reflux for 2 h. The reaction mixture was cooled to room temperature, poured into 0.5 M NaOH aqueous solution, stirred for 1 hour and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by a silica gel column chromatography (silica gel: Wako Gel (C200), eluent: chloroform / methanol = 10 : 1) to give 8-(4-bromo- 2,6-dimethyl-phenyl)-4-mercapto-2-methyl-pyrrolo [ 1 ,2-α]pyrimidine-6-carbonitrile (7.52 g).
(2) A mixture of 8-(4-bromo-2,6-dimethyl-phenyl)-4-mercapto-2-methyl- pyrrolo[l,2-β]pyrimidine-6-carbonitrile (7.50 g), Mel (12.5 mL) in 1 MNaOH aqueous solution (100 mL) was stirred at room temperature for 1 h. The reaction mixture was extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to give crude 8-(4-bromo-2,6-dimethyl-phenyl)-2-methyl-4- methylsulfanyl-pyrrolo[l,2-β]pyrimidine-6-carbonitrile (5.75 g). This product was used in the next step without further purification.
Figure imgf000016_0002
(3) 8-(4-bromo-2,6-dimethyl-phenyl)-2-methyl-4-methylsulfanyl- pyrrolo[l,2-α]pyrimidine-6-carbonitrile (5.70 g) was added into cone. H2SO4 (100 mL) and heated for 60 °C for 5 hours. The reaction mixture was cooled to room temperature, poured into ice- water and then 10% aqueous NaOH solution was added to make the aqueous mixture alkaline (pH = 8) and extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by a silica gel column chromatography (silica gel: Wako Gel (C200), eluent: ethyl acetate) to give 8-(4-bromo-2,6-dimethyl-phenyl)-2-methyl-4- methylsulfanyl-pyrrolo[l,2-«]pyrimidine-6-carboxylic acid amide (3.12 g).
Figure imgf000017_0001
(4) To a solution of Oxone (9.12g) in water (50 mL) was added a solution of 8-(4-bromo-2,6-dimethyl-phenyl)-2-methyl-4-methylsulfanyl-pyrrolo [ 1 ,2- a]pyrimidine-6-carboxylic acid amide (3.00 g) in ethanol (50 mL) in an ice-cooling bath. The reaction mixture was stirred under ice-cooling for 30 minutes, poured into water and extracted with ethyl acetate. The organic layer was washed with a saturated aqueous sodium hydrogencarbonate and brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by a silica gel column chromatography (silica gel: Wako Gel (C200), eluent: ethyl acetate) to give 8-(4-bromo-2,6-dimethyl-phenyl)-4- methanesulfinyl-2-methyl-pyrrolo[l ,2-α]pyrimidine-6-carboxylic acid amide (1.68 g).
Figure imgf000017_0002
(5) A mixture of 8-(4-bromo-2,6-dimethyl-phenyl)-4-methanesulfinyl-2- methyl-pyrrolo[l,2- ]pyrimidine-6-carboxylic acid amide (100 mg), N,N- dipropylamine (48 mg) in ethanol (1 mL) was heated at reflux for 1 h. The reaction mixture was cooled to room temperature, poured into a saturated aqueous sodium hydrogencarbonate, and then extracted with ethyl acetate. The organic layer was washed with brine, dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by a silica gel column chromatography (silica gel: Wako Gel (C200), eluent: hexane / ethyl acetate = 1 : 1) to give a solid. The solid was washed with a mixture of diisopropylether and ethyl acetate to give the title compound (50 mg).
Table 1 lists the compound obtained in Example 2 and compounds obtained by the similar procedure as described in Example 2.
Table l*1
Figure imgf000019_0001
melting point
Com. Ex. Rl R3 (°C)
No. No. (solvent for Ar crystallization)
Figure imgf000019_0002
1-003 CH3 H -Br 213-215*2 (EtOAc/EtOH)
Figure imgf000019_0003
1-004 Br 204-206*2 (EtOAc/EtOH)
Figure imgf000019_0004
1-005 CH3 H .Br 203-205 *2 (EtOAc/EtOH)
Figure imgf000019_0005
Br
Figure imgf000019_0006
1-007 CH3 H -Br 166-168*2 NH (EtOAc/EtOH)
1-008 1 H3 175-177*2 (EtOAc/EtOH)
Figure imgf000019_0007
H)
Figure imgf000019_0008
-010 1 o CH3 H Br 160-162*2 (EtOAc/EtOH) ^NH I -011 'CHa 172-174*2 (EtOAc/EtOH)
Figure imgf000020_0001
Figure imgf000020_0002
-017 1 CH3 H ΛABΓ 163-165*2*3
Figure imgf000020_0003
Figure imgf000020_0004
-019 2 CH3 H 232-234 (decomp.) (EtOAc)
Figure imgf000020_0006
Figure imgf000020_0005
Figure imgf000020_0007
-021 2 H3co 208-210 (EtOAc)
Figure imgf000020_0008
Figure imgf000021_0001
1-024 amorphous
Figure imgf000021_0002
Figure imgf000021_0003
1-028 CH3 H amorphous
Figure imgf000021_0005
Figure imgf000021_0004
* 1 : Com. No. = compound number, Ex. No. = example number, solvent for crystallization; EtOAc = ethyl acetate, EtOH = ethanol Analytical data of non-crystal compounds are described below. 1-024:
MS (Pos, ES): 442 (M + Na)+, 444 (M + Na + 2)+; NMR (300 MHz, CDC13) δ 2.04 (3 H, s), 2.09 (3 H, s), 2.58 (3 H, s), 3.17 (3 H, s), 5.54-5.66 (2 H, m), 7.26 (1 H, s), 7.31 (2 H, s), 7.59 (l H, s)
1-028:
MS (Pos, ES): 486 (M + 1)+, 488 (M + 3)+, 508 (M + Na)+, 510 (M + Na + 2)+; NMR (300 MHz, CDC13) δ 0.98 (3 H, t, J = 7.3 Hz), 1.40-1.64 (2 H, m), 1.68-1.79 (2 H, m), 2.09 (3 H, s), 2.10 (3 H, s), 2.37 (3 H, s), 2.51 (1 H, dd, J = 5.9, 14.4 Hz), 2.65 (1 H, dd, J - 7.4, 14.4 Hz), 4.07-4.18 (1 H, m), 5.28-5.39 (1 H, br s), 5.48-5.58 (2 H, br s), 5.72-5.87 (1 H, br s), 5.89 (1 H, s), 7.22 (1 H, s), 7.26 (3 H, s), 10.75- 10.92 (l H, br s)
*2: HCl salt (Compound 1-015 is 2HC1 salt)
*3: Crystallized on standing from the compound purified (silica gel column chromatography) and dried.
Table 2 *ι
Figure imgf000023_0001
melting point
Com. Ex. (°C) R2 R3
No. No. R: Ar (solvent for crystallization)
Figure imgf000023_0002
* 1 : Com. No. = compound number, Ex. No. = example number, solvent for crystallization; EtOAc = ethyl acetate, IPE = diisopropylether
*2: HCl salt Test Example [CRF receptor binding test] Monkey amygdala membranes were used as a receptor preparation. 125I-CRF was used as 125I-labeled ligand. Binding reaction using the 125I-labeled ligand was carried out by the following method described in The Journal of Neuroscience, 7, 88 (1987).
Preparation of receptor membranes: Monkey amygdala was homogenized in 50 mM Tris-HCl buffer (pH 7.0) containing 10 mM MgCl2, 2 mM EDTA and centrifuged at 48,000 x g for 20 min, and the precipitate was washed once with Tris-HCl buffer. The washed precipitate was suspended in 50 mM Tris-HCl buffer (pH 7.0) containing 10 mM MgCl2, 2 mM
EDTA, 0.1% bovine serum albumin and 100 kallikrein units/ml aprotinin, to obtain a membrane preparation.
CRF receptor binding test: The membrane preparation (0.3 mg protein/ml), 125I-CRF (0.2 nM) and a test drug were reacted at 25°C for 2 hours. After completion of the reaction, the reaction mixture was filtered by suction through a glass filter (GF/C) treated with
0.3% polyethylene imine, and the glass filter was washed three times with phosphate-buffered saline containing 0.01% Triton X-100. After the washing, the radioactivity of the filter paper was measured in a gamma counter. The amount of I-CRF bound when the reaction was carried out in the presence of 1 μM CRF was taken as the degree of nonspecific binding of 125I-CRF, and the difference between the total degree of I-CRF binding and the degree of nonspecific 125I-CRF binding was taken as the degree of specific 125I-CRF binding.
An inhibition curve was obtained by reacting a definite concentration (0.2 nM) of 125I-CRF with various concentrations of each test drug under the conditions described above. A concentration of the test drug at which binding of 1 5I-CRF is inhibited by 50% (IC50) was determined from the inhibition curve. As a result, it was found that compounds 1-001, 1-002, 1-003, 1-004, 1-005,
1-006, 1-007, 1-008, 1-009, 1-010, 1-011, 1-012, 1-013, 1-016, 1-017, 1-018, 1-019, 1-022, 1-027, 2-001, 2-002, 2-003, 2-004, 2-005 and 2-006 can be exemplified as typical compounds having an IC50 value of 100 nM or less.
EFFECT OF THE INVENTION According to the present invention, compounds having a high affinity for CRF receptors have been provided. These compounds are effective against diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastral diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alpecia, irritable bowel syndrome, sleep disorders, dermatitides, schizophrenia, pain, etc.

Claims

CLAIMS 1. A pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group represented by the following formula [I]:
Figure imgf000026_0001
(wherein E is N or CR10; R1 is -OR4, -S(O),R4 or -NR4R5; R2 is hydrogen, Cι-6alkyl, C3-7cycloalkyl, C3- cycloalkyl-C1-6alkyl, halogen, C1-6alkoxy, C3-7cycloalkyloxy, Cι-6alkylthio or -N(R6)R7; R3 is hydrogen, C1-6alkyl, C3-7cycloalkyl, C3-7cycloalkyl-C1-6alkyl or aryl; R4 and R5 are the same or different, and independently hydrogen, Cι- alkyl, C3-7cycloalkyl, C3_7cycloalkyl-C1-6alkyl, di(C3-7cycloalkyl)-C1-6alkyl, C1-6alkoxy-Cι- 6alkyl, di(Cι-6alkoxy)-Cι-6alkyl, hydroxy-Cι-6alkyl, cyano-C1-6alkyl, carbamoyl-Ci- 6alkyl or di(C1-6alkyl)amino-C2-6alkyl; or R4 and R5 are taken together to form - (CH2)m-A-(CH2)n- wherein A is methylene, oxygen, sulfur, NR8 or CHR9; R and R are the same or different, and independently hydrogen or C\. 6alkyl; R is hydrogen, Cι-6alkyl, C3-7cycloalkyl, aryl or aryl-C1-6alkyl; R9 is hydrogen, hydroxy, hydroxy-C1- alkyl, cyano or cyano-C1-6alkyl; R10 is hydrogen, halogen or C1-6alkyl; 1 is an interger selected from 0, 1 and 2; m is an integer selected from 1, 2, 3 and 4; n is an integer selected from 0, 1, 2 and 3; with the proviso, when A is oxygen, sulfur or NR8, then n is 1, 2 or 3; Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of halogen, C1-6alkyl, C3-7cycloalkyl, C2-6alkenyl, C2- 6alkynyl, C1-6alkoxy, C1-6alkylthio, Cι-6alkylsulfinyl, Cι-6alkylsulfonyl, cyano, nitro, hydroxy, -CO2Rn, -C(=O)R12, -CONR13R14, -OC(=O)R15, -NR16C02R17, - S(=O)rNR18R19, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R20)R21; R11 and R17 are the same or different, and independently are hydrogen, Cι_ 5alkyl, C3-8cycloalkyl, C .8cycloalkyl-Cι.5alkyl, aryl or aryl-Cι-5alkyl; R12, R13, R14, R15, R16, R18, R19, R20 and R21 are the same or different, and independently are hydrogen, C1-5alkyl or C3-8cycloalkyl; r is 1 or 2), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
2. The pyrrolopyrimidine derivative substituted with a carbamoyl group according to claim 1 represented by the following formula [II]:
Figure imgf000027_0001
(wherein R1, R2, R3 and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
3. The pyrrolopyrimidine derivative substituted with a carbamoyl group according to claim 2 represented by the formula [II], wherein R1 is -OR4 or -NR4R5; R2 is C1-6alkyl; R3 is hydrogen or C1-6alkyl; R4 and R5 are the same or different, and independently hydrogen, C1-9alkyl, C3_ cycloalkyl, C3-7cycloalkyl-Cι-6alkyl, di(C3-
Figure imgf000027_0002
C1-6alkoxy-C1-6alkyl, di(Cι-6alkoxy)-C1-6alkyl, hydroxy-Cϊ. 6alkyl or cyano-Cι-6alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, Cι-3alkyl, C1-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and - N(R20)R21 (wherein R20 and R21 are the same or different, and independently are hydrogen or Cι-3alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
4. The pyrrolopyrimidine derivative substituted with a carbamoyl group according to claim 2 represented by the formula [II], wherein R1 is -OR4 or -NR4R5;
R2 is C1-6alkyl; R3 is hydrogen or Cι-6alkyl; R4 is Cι-9alkyl, C3- cycloalkyl, C3-
7cycloalkyl-Cι-6alkyl, di(C3- cycloalkyl)-Cι-6alkyl, Cι-6alkoxy-Cι-6alkyl, di(Cι.
6alkoxy)-C1-6alkyl, hydroxy-Cι-6alkyl or cyano-Cι-6alkyl; R5 is hydrogen; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C^aUcyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
5. The pyrrolotriazine derivative substituted with a carbamoyl group according to claim 1 represented by the following formula [III]:
Figure imgf000028_0001
(wherein R1, R2, R3 and Ar are as defined in claim 1), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
6. The pyrrolotriazine derivative substituted with a carbamoyl group according to claim 5 represented by the formula [III], wherein R1 is -OR4 or -NR4R5; R2 is C1-6alkyl; R3 is hydrogen or C1-6alkyl; R4 and R5 are the same or different, and independently hydrogen, Cι- alkyl, C3_7cycloalkyl, C3- cycloalkyl-C1-6alkyl, di(C3- 7cycloalkyl)-C1-6alkyl,
Figure imgf000028_0002
di(Cι-6alkoxy)-Cι-6alkyl, hydroxy-Cμ 6alkyl or cyano-C1-6alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C1-3alkyl, Cι-3alkoxy, C1-3alkylthio, trifluoromethyl, trifluoromethoxy and - N(R )R (wherein R and R are the same or different, and independently are hydrogen or C1-3alkyl), individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
7. The pyrrolotriazine derivative substituted with a carbamoyl group according to claim 5 represented by the formula [III], wherein R1 is -OR4 or -NR4R5; R2 is C1-6alkyl; R3 is hydrogen or Cι-6alkyl; R4is C1-9alkyl, C3-7cycloalkyl, C3- •/cycloalkyl-d-δalkyl, di(C3-7cycloalkyl)-Cι-6alkyl, C1-6alkoxy-Cι-6alkyl, di(d. 6alkoxy)-Cι-6alkyl, hydroxy-Cι-6alkyl or cyano-C1-6alkyl; R5 is hydrogen; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C1-3alkyl, individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.
8. An antagonist for CRF receptors, comprising a pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claims 1 to 7, as an active ingredient.
9. Use of a pyrrolopyrimidine or pyrrolotriazine derivative substituted with a carbamoyl group, a pharmaceutically acceptable salt thereof or its hydrate according to any one of claim 1 to 7, for the manufacture of a therapeutic agent as an antagonist for CRF receptors.
PCT/JP2005/000319 2004-01-06 2005-01-06 Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists WO2005066142A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
US10/584,946 US8106194B2 (en) 2004-01-06 2005-01-06 Pyrrolopyrimidine and pyrrolotriazine derivatives
EP05703558A EP1706410A2 (en) 2004-01-06 2005-01-06 Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists
JP2006546614A JP4742273B2 (en) 2004-01-06 2005-01-06 Pyrrolopyrimidine and pyrrolotriazine derivatives
CN2005800020220A CN1910185B (en) 2004-01-06 2005-01-06 Pyrrolopyrimidine and pyrrolotriazine derivatives as CRF receptor antagon
CA2552503A CA2552503C (en) 2004-01-06 2005-01-06 Pyrrolopyrimidine and pyrrolotriazine derivatives
HK07103339.7A HK1097539A1 (en) 2004-01-06 2007-03-29 Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004001311 2004-01-06
JP2004-001311 2004-01-06

Publications (2)

Publication Number Publication Date
WO2005066142A2 true WO2005066142A2 (en) 2005-07-21
WO2005066142A3 WO2005066142A3 (en) 2005-10-13

Family

ID=34746977

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2005/000319 WO2005066142A2 (en) 2004-01-06 2005-01-06 Pyrrolopyrimidine and pyrrolotriazine derivatives as crf receptor antagonists

Country Status (8)

Country Link
US (1) US8106194B2 (en)
EP (1) EP1706410A2 (en)
JP (1) JP4742273B2 (en)
CN (1) CN1910185B (en)
CA (1) CA2552503C (en)
HK (1) HK1097539A1 (en)
RU (1) RU2367663C2 (en)
WO (1) WO2005066142A2 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365078B2 (en) 2004-01-06 2008-04-29 Taisho Pharmaceutical Co., Ltd. Triaza-cyclopenta[cd]indene derivatives
US7557111B2 (en) 2004-01-06 2009-07-07 Taisho Pharmaceutical Co., Ltd. Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
US7951811B2 (en) 2004-06-25 2011-05-31 Taisho Pharmaceutical Co., Ltd. Pyrrolo[2,3-D]pyrimidine derivatives substituted with a cyclic amino group
US8106194B2 (en) 2004-01-06 2012-01-31 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolotriazine derivatives
WO2017004408A1 (en) * 2015-07-01 2017-01-05 Northwestern University Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736018C (en) * 2008-09-16 2015-11-03 Stephanie Merchant Compositions for treating or delaying the onset of hair loss

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0729758A2 (en) * 1995-03-02 1996-09-04 Pfizer Inc. Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
WO1998008847A1 (en) * 1996-08-28 1998-03-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
WO1998035967A2 (en) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE177101T1 (en) 1992-12-17 1999-03-15 Pfizer PYRROLOPYRIMIDINES AS CRF ANTAGONISTS
PT882051E (en) 1996-02-07 2002-04-29 Janssen Pharmaceutica Nv THYOPHENOPYRIMIDINES
KR20010005568A (en) 1997-03-26 2001-01-15 우에하라 아끼라 4-Tetrahydropyridylpyrimidine Derivatives
CA2272292A1 (en) 1997-04-22 1998-10-29 Janssen Pharmaceutica N.V. Crf antagonistic thiophenopyridines
WO1999051599A1 (en) 1998-04-02 1999-10-14 Neurogen Corporation Aminoalkyl substituted pyrrolo[2,3-b]pyridine and pyrrolo[2,3-d]pyrimidine derivatives: modulators of crf1 receptors
AU3375999A (en) 1998-04-02 1999-10-25 Neurogen Corporation Aminoalkyl substituted 5,6,7,8-tetrahydro-9h pyrimidino(2,3-b)indole and 5,6,7,8-tetrahydro-9h-pyrimidino(4,5-b)indole derivatives: crf1 specific ligands
EP1068207A1 (en) 1998-04-02 2001-01-17 Neurogen Corporation AMINOALKYL SUBSTITUTED 9H-PYRIDINO 2,3-b]INDOLE AND 9H-PYRIMIDINO 4,5-b]INDOLE DERIVATIVES
EP1176146B1 (en) 1999-03-11 2005-06-08 Taisho Pharmaceutical Co., Ltd Carbamoyl tetrahydropyridine derivatives
AR028782A1 (en) 2000-07-05 2003-05-21 Taisho Pharmaceutical Co Ltd TETRAHYDROPIRIDINE OR PIPERIDINE HETEROCICLIC DERIVATIVES
TWI270549B (en) 2002-12-26 2007-01-11 Taisho Pharmaceutical Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with cyclic amino group
RU2006128600A (en) 2004-01-06 2008-02-20 Тайсо Фармасьютикал Ко., Лтд. (Jp) DERIVATIVES OF TRIAZACYCLOPENT [cd] INDENA
CA2552503C (en) 2004-01-06 2011-09-13 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolotriazine derivatives
WO2005066182A1 (en) 2004-01-06 2005-07-21 Taisho Pharmaceutical Co., Ltd. Thienopyrimidine and thienopyridine derivatives substituted with cyclic amino group
EP1725562A1 (en) 2004-03-05 2006-11-29 Taisho Pharmaceutical Co., Ltd Pyrrolopyrimidine derivatives
WO2006001501A1 (en) 2004-06-25 2006-01-05 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with tetrahydropyridine as crf antagonists
JP2007161585A (en) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd Pyrrolopyrimidine and pyrrolopyridine derivative substituted with cyclic amino group

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0729758A2 (en) * 1995-03-02 1996-09-04 Pfizer Inc. Pyrazolopyrimidines and pyrrolopyrimidines for treatment of neuronal and other disorders
WO1998008847A1 (en) * 1996-08-28 1998-03-05 Pfizer Inc. Substituted 6,5-hetero-bicyclic derivatives
WO1998035967A2 (en) * 1997-02-18 1998-08-20 Neurocrine Biosciences, Inc. Biazacyclic crf antagonists

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7365078B2 (en) 2004-01-06 2008-04-29 Taisho Pharmaceutical Co., Ltd. Triaza-cyclopenta[cd]indene derivatives
US7557111B2 (en) 2004-01-06 2009-07-07 Taisho Pharmaceutical Co., Ltd. Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
US8106194B2 (en) 2004-01-06 2012-01-31 Taisho Pharmaceutical Co., Ltd. Pyrrolopyrimidine and pyrrolotriazine derivatives
US7951811B2 (en) 2004-06-25 2011-05-31 Taisho Pharmaceutical Co., Ltd. Pyrrolo[2,3-D]pyrimidine derivatives substituted with a cyclic amino group
WO2017004408A1 (en) * 2015-07-01 2017-01-05 Northwestern University Substituted 4-methyl-pyrrolo[1.2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
US9802942B2 (en) 2015-07-01 2017-10-31 Northwestern University Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
US10040799B2 (en) 2015-07-01 2018-08-07 Northwestern University Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
JP2018522872A (en) * 2015-07-01 2018-08-16 ノースウェスタン ユニバーシティ Substituted 4-methylpyrrolo [1,2-A] pyrimidine-8-carboxamide compounds and their use for modulation of glucocerebrosidase activity
US10227352B2 (en) 2015-07-01 2019-03-12 Northwestern University Substituted 4-methyl-pyrrolo[1,2-A]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity
US10442812B2 (en) 2015-07-01 2019-10-15 Northwestern University Substituted 4-methyl-pyrrolo[1,2-a]pyrimidine-8-carboxamide compounds and uses thereof for modulating glucocerebrosidase activity

Also Published As

Publication number Publication date
JP2007517794A (en) 2007-07-05
RU2006128581A (en) 2008-02-20
HK1097539A1 (en) 2007-06-29
CN1910185A (en) 2007-02-07
US20110137031A1 (en) 2011-06-09
US8106194B2 (en) 2012-01-31
CN1910185B (en) 2010-05-26
CA2552503C (en) 2011-09-13
JP4742273B2 (en) 2011-08-10
CA2552503A1 (en) 2005-07-21
EP1706410A2 (en) 2006-10-04
RU2367663C2 (en) 2009-09-20
WO2005066142A3 (en) 2005-10-13

Similar Documents

Publication Publication Date Title
US20070270588A1 (en) Pyrrolopyrimidine Derivatives
AU2005257496B2 (en) Pyrrolopyrimidine and pyrrolopyridine derivatives substituted with a cyclic amino group as CRF antagonists
US7557111B2 (en) Substituted thieno[3,2-d]pyrimidines as CRF receptor antagonists
US20070293670A1 (en) Pyrrolopyrimidine and Pyrrolopyridine Derivatives Substituted with Tetrahydropyridine as Crf Antagonists
EP1704149B1 (en) Triaza-cyclopenta[cd]indene derivatives
US8106194B2 (en) Pyrrolopyrimidine and pyrrolotriazine derivatives
AU2004222596A1 (en) 8-substituted-6, 7, 8, 9-tetrahydropyrimido(1,2-a) pyrimidin-4-one derivatives
WO2009008552A1 (en) 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives
JP2007169216A (en) Pyrrolopyrimidine and pyrrolopyridine derivative substituted with cyclic amino group

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2005703558

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2552503

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 10584946

Country of ref document: US

Ref document number: 2006546614

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 200580002022.0

Country of ref document: CN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006128581

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2005703558

Country of ref document: EP